Genzyme in the UK

Genzyme in the UK is dedicated to making a positive impact on the lives of people with serious diseases. Operating out of two locations we draw on the diverse talents of a 500-strong team. More>

10-year follow-up data on Lemtrada® (alemtuzumab) detailing clinical efficacy in people with relapsing-remitting multiple sclerosis (MS) to be presented at the American Academy of Neurology (AAN) 2016 Annual Meeting

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that a new long-term analysis detailing 10 years of clinical efficacy of Lemtrada® (alemtuzumab) in people with relapsing-remitting multiple sclerosis (RRMS) will be presented at the 68th American Academy of Neurology (AAN) 2016 Annual Meeting in Vancouver, Canada, 15-21 April 2016. More>

Sanofi Genzyme Recognises 2016 International Rare Disease Day with Premiere of Expression of Hope film

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced its support of International Rare Disease Day by showing the premiere of a short film based on artwork produced through its Expression of Hope programme. More>

Sanofi Genzyme Announces UK Recipient of 2015 Annual Patient Advocacy Leadership (PAL) Awards Programme

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the UK-based International Niemann-Pick Disease Alliance (INPDA) has received one of its 2015 Patient Advocacy Leadership (PAL) Awards. More>

Genzyme Announces UK Opening of Expression of Hope Art Exhibition at Rare Diseases Conference

Genzyme, a Sanofi company, welcomes the UK opening of the international Expression of Hope exhibition at the Association for Glycogen Storage Disease UK (AGSD-UK) annual conference 2015 in Wyboston Lakes, Bedfordshire, UK. More>

Search

Discover more about Genzyme's purpose, legacy, and innovation in our corporate brochure.

          

 

 

'